Outset Medical Inc is a medical technology company pioneering a technology to reduce the cost and complexity of dialysis. The Company generates revenue from the sales of Tablo consoles and related consumables, including Tablo cartridges and accessories.
Last trade$3.22
Day change-$0.17 (-5.01%)
Day range$3.14 – $3.82
Volume91,669
Market cap$64M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$63.98M
Price / earnings
—
Price / book
0.77×
Price / sales
0.52×
EV / sales
1.07×
EV / EBITDA
-2.19×
Profitability
Earnings per share
-$3.77
Return on assets
-30.88%
Return on equity
-85.39%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.2×
Current ratio
4.86×
Quick ratio
3.85×
Cash ratio
0.76×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$42.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$33.6M
$31.64M
$27.86M
$28.87M
$29.43M
$31.42M
$29.75M
$29.47M
Cost of revenue
$19.93M
$18.35M
$15.77M
$16.64M
$17.84M
$19.55M
$18.69M
$18.72M
Gross profit
$13.67M
$13.28M
$12.1M
$12.23M
$11.59M
$11.87M
$11.07M
$10.75M
Selling, general and administrative
$20.04M
$23.51M
$23.4M
$24.81M
$22.03M
$23.44M
$21.95M
$24.72M
Research and development
$5.9M
$5.45M
$5.62M
$5.06M
$5.38M
$5.29M
$5.52M
$7.89M
Total operating expenses
$25.94M
$28.96M
$29.01M
$29.86M
$27.4M
$28.73M
$27.47M
$32.61M
Operating income
-$12.27M
-$15.68M
-$16.92M
-$17.63M
-$15.81M
-$16.87M
-$16.4M
-$21.86M
Interest expense
-$3.51M
-$3.44M
-$3.37M
-$3.44M
-$3.48M
-$3.48M
-$3.56M
-$5.83M
Income before taxes
-$14.53M
-$17.76M
-$18.76M
-$19.4M
-$17.43M
-$18.44M
-$25.67M
-$25.64M
Income taxes
$153K
$220K
$217K
$95K
$404K
$104K
$115K
-$4K
Net income
-$14.69M
-$17.98M
-$18.98M
-$19.49M
-$17.84M
-$18.54M
-$25.78M
-$25.64M
Net income attributable to common shareholders
-$14.69M
-$17.98M
-$18.98M
-$19.49M
-$17.84M
-$18.54M
-$25.78M
-$25.64M
EBITDA
-$11.6M
-$15.05M
-$16.12M
-$16.75M
-$14.8M
-$15.71M
-$15.11M
-$20.45M
Basic earnings per share
-$0.78
-$0.97
-$1.03
-$1.07
-$1.00
-$1.04
-$3.66
-$7.29
Diluted earnings per share
-$0.78
-$0.97
-$1.03
-$1.07
-$1.00
-$1.04
-$3.66
-$7.29
Recent news
Company coverage with links to the original publishers.
Outset Medical, Inc. (OM) received an upgrade to Zacks Rank #2 (Buy) due to rising earnings estimate revisions over the past three months, positioning it in the top 20% of Zacks-covered stocks. The upgrade reflects improving business fundamentals and suggests potential near-term stock price appreciation.
DaVita (DVA) has rallied 55.8% year-to-date, driven by strong Integrated Kidney Care (IKC) platform growth, improving treatment volumes, and technology investments. The company beat Q2 expectations by $40 million in adjusted operating income and raised full-year guidance. However, persistent headwinds include declining revenue per treatment due to commercial-mix pressure (estimated $70 million impact in 2027), elevated G&A costs limiting operating leverage, and limited acquisition opportunities in a consolidated market.
Hims & Hers (HIMS) is accelerating growth through weight loss offerings, international expansion, and AI-enabled care, with U.S. revenues up 16% and international revenues surging 17-fold. However, the company faces headwinds from gross margin compression due to lower-margin branded products, negative cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock has gained 49.5% in six months but carries a Zacks Rank #3 (Hold) rating.
Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.
U.S. stock futures fell on Tuesday after the Senate passed a resolution to reopen the government. Market attention was focused on several company earnings reports and potential Federal Reserve interest rate cuts.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.